Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.33 USD
226.45 M USD
957.80 M USD
167.39 M
About ACADIA Pharmaceuticals Inc.
Sector
Industry
CEO
Catherine Owen Adams
Website
Headquarters
San Diego
Founded
1993
ISIN
US0042251084
FIGI
BBG000BHG9K0
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BOATS exchange ACADIA Pharmaceuticals Inc. stocks are traded under the ticker ACAD.
We've gathered analysts' opinions on ACADIA Pharmaceuticals Inc. future price: according to them, ACAD price has a max estimate of 40.00 USD and a min estimate of 17.00 USD. Watch ACAD chart and read a more detailed ACADIA Pharmaceuticals Inc. stock forecast: see what analysts think of ACADIA Pharmaceuticals Inc. and suggest that you do with its stocks.
ACAD reached its all-time high on Jul 14, 2023 with the price of 37.31 USD, and its all-time low was 14.17 USD and was reached on Apr 8, 2025. View more price dynamics on ACAD chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Yes, you can track ACADIA Pharmaceuticals Inc. financials in yearly and quarterly reports right on TradingView.
ACADIA Pharmaceuticals Inc. is going to release the next earnings report on Nov 11, 2025. Keep track of upcoming events with our Earnings Calendar.
ACAD earnings for the last quarter are 0.16 USD per share, whereas the estimation was 0.14 USD resulting in a 15.88% surprise. The estimated earnings for the next quarter are 0.14 USD per share. See more details about ACADIA Pharmaceuticals Inc. earnings.
ACADIA Pharmaceuticals Inc. revenue for the last quarter amounts to 264.57 M USD, despite the estimated figure of 262.02 M USD. In the next quarter, revenue is expected to reach 276.70 M USD.
ACAD net income for the last quarter is 26.67 M USD, while the quarter before that showed 18.99 M USD of net income which accounts for 40.44% change. Track more ACADIA Pharmaceuticals Inc. financial stats to get the full picture.
No, ACAD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 9, 2025, the company has 654 employees. See our rating of the largest employees — is ACADIA Pharmaceuticals Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ACADIA Pharmaceuticals Inc. EBITDA is 103.97 M USD, and current EBITDA margin is 10.46%. See more stats in ACADIA Pharmaceuticals Inc. financial statements.
Like other stocks, ACAD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ACADIA Pharmaceuticals Inc. stock right from TradingView charts — choose your broker and connect to your account.